News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ogenix Corporation Announces Intent to License EpiFLO SD(R) Technology to Minerva Healthcare


5/18/2007 11:52:07 AM

CLEVELAND & SAN FRANCISCO--(BUSINESS WIRE)--Ogenix Corporation today announced that it has agreed to grant an option to license its Transdermal Sustained Oxygen Therapy (TSOT) technology for wound healing and the treatment of skin disorders to Minerva Healthcare, Inc., for worldwide (except in Canada) distribution of its EpiFLO SDĀ® family of products.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES